Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy. / Jørgen Jennum, Poul; Østergaard Pedersen, Lars; Czarna Bahl, Justyna Maria; Modvig, Signe; Fog, Karina; Holm, Anja; Rahbek Kornum, Birgitte; Gammeltoft, Steen.

In: Sleep, Vol. 40, No. 1, zsw006, 01.01.2017.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jørgen Jennum, P, Østergaard Pedersen, L, Czarna Bahl, JM, Modvig, S, Fog, K, Holm, A, Rahbek Kornum, B & Gammeltoft, S 2017, 'Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy', Sleep, vol. 40, no. 1, zsw006. https://doi.org/10.1093/sleep/zsw006

APA

Jørgen Jennum, P., Østergaard Pedersen, L., Czarna Bahl, J. M., Modvig, S., Fog, K., Holm, A., Rahbek Kornum, B., & Gammeltoft, S. (2017). Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy. Sleep, 40(1), [zsw006]. https://doi.org/10.1093/sleep/zsw006

Vancouver

Jørgen Jennum P, Østergaard Pedersen L, Czarna Bahl JM, Modvig S, Fog K, Holm A et al. Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy. Sleep. 2017 Jan 1;40(1). zsw006. https://doi.org/10.1093/sleep/zsw006

Author

Jørgen Jennum, Poul ; Østergaard Pedersen, Lars ; Czarna Bahl, Justyna Maria ; Modvig, Signe ; Fog, Karina ; Holm, Anja ; Rahbek Kornum, Birgitte ; Gammeltoft, Steen. / Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy. In: Sleep. 2017 ; Vol. 40, No. 1.

Bibtex

@article{3d284db56cd040b2a99c80bf646aab0f,
title = "Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy",
abstract = "Objectives: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration.Methods: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases), aged 33 years on average and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of the levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1).Results: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ± 143.5 pg/mL) and type 2 narcolepsy (455.9 ± 65.0 pg/mL) compared to controls (697.9 ± 167.3 pg/mL, p < .05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/mL) and P-tau181 (19.1 ± 4.3 pg/mL) were lower than in controls (162.2 ± 49.9 pg/mL and 33.8 ± 9.2 pg/mL, p < .05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals.Conclusion: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in the central nervous system.",
keywords = "Adult, Amyloid beta-Peptides/cerebrospinal fluid, Biomarkers/cerebrospinal fluid, Case-Control Studies, Chitinase-3-Like Protein 1/cerebrospinal fluid, Female, Humans, Hypersomnolence, Idiopathic/cerebrospinal fluid, Male, Narcolepsy/cerebrospinal fluid, Neurodegenerative Diseases/cerebrospinal fluid, Neurofilament Proteins/cerebrospinal fluid, Orexins/cerebrospinal fluid, alpha-Synuclein/cerebrospinal fluid, tau Proteins/cerebrospinal fluid",
author = "{J{\o}rgen Jennum}, Poul and {{\O}stergaard Pedersen}, Lars and {Czarna Bahl}, {Justyna Maria} and Signe Modvig and Karina Fog and Anja Holm and {Rahbek Kornum}, Birgitte and Steen Gammeltoft",
note = "{\textcopyright} Sleep Research Society 2016. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.",
year = "2017",
month = jan,
day = "1",
doi = "10.1093/sleep/zsw006",
language = "English",
volume = "40",
journal = "Sleep (Online)",
issn = "0161-8105",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy

AU - Jørgen Jennum, Poul

AU - Østergaard Pedersen, Lars

AU - Czarna Bahl, Justyna Maria

AU - Modvig, Signe

AU - Fog, Karina

AU - Holm, Anja

AU - Rahbek Kornum, Birgitte

AU - Gammeltoft, Steen

N1 - © Sleep Research Society 2016. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objectives: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration.Methods: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases), aged 33 years on average and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of the levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1).Results: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ± 143.5 pg/mL) and type 2 narcolepsy (455.9 ± 65.0 pg/mL) compared to controls (697.9 ± 167.3 pg/mL, p < .05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/mL) and P-tau181 (19.1 ± 4.3 pg/mL) were lower than in controls (162.2 ± 49.9 pg/mL and 33.8 ± 9.2 pg/mL, p < .05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals.Conclusion: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in the central nervous system.

AB - Objectives: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration.Methods: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases), aged 33 years on average and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of the levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1).Results: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ± 143.5 pg/mL) and type 2 narcolepsy (455.9 ± 65.0 pg/mL) compared to controls (697.9 ± 167.3 pg/mL, p < .05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/mL) and P-tau181 (19.1 ± 4.3 pg/mL) were lower than in controls (162.2 ± 49.9 pg/mL and 33.8 ± 9.2 pg/mL, p < .05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals.Conclusion: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in the central nervous system.

KW - Adult

KW - Amyloid beta-Peptides/cerebrospinal fluid

KW - Biomarkers/cerebrospinal fluid

KW - Case-Control Studies

KW - Chitinase-3-Like Protein 1/cerebrospinal fluid

KW - Female

KW - Humans

KW - Hypersomnolence, Idiopathic/cerebrospinal fluid

KW - Male

KW - Narcolepsy/cerebrospinal fluid

KW - Neurodegenerative Diseases/cerebrospinal fluid

KW - Neurofilament Proteins/cerebrospinal fluid

KW - Orexins/cerebrospinal fluid

KW - alpha-Synuclein/cerebrospinal fluid

KW - tau Proteins/cerebrospinal fluid

U2 - 10.1093/sleep/zsw006

DO - 10.1093/sleep/zsw006

M3 - Journal article

C2 - 28364448

VL - 40

JO - Sleep (Online)

JF - Sleep (Online)

SN - 0161-8105

IS - 1

M1 - zsw006

ER -

ID: 196169120